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Introduction
Figures 1A & 1B: Peritoneal carcinomatosis from signet ring cell gastric 
carcinoma in a 63-year-old woman who complained of diffuse abdominal 
pain. Enhanced computed tomographic (CT) images in the level of the liver 
show a large amount of ascites (white arrows), nodular soft tissue thickening 
of the subdiaphragmatic peritoneum (black arrows).
Gastric cancer is present and also known for its aggressive behavior and is the second 
main cause of death from cancer worldwide accounting for 740,000 deaths per year [1,2]. 
Incidence rates of gastric cancer vary throughout the world, but with two-thirds occurring in 
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Abstract
Peritoneal carcinomatosis (PC) is an important and not rare cause of morbidity and mortality among 
patients with gastric cancer. Younger age(less than 65 years) female gender, advanced T- and N-stage, a 
primary tumor of signet ring cells or linitis plastica, and primary tumors covering multiple anatomical 
locations of the stomach were all associated with a higher odds ratios of developing PC. PC is a frequent 
condition in patients presenting with gastric cancer, especially in younger patients with advanced tumor 
stages. In this article, we present a case of a 63 years old woman who was operatively treated for gastric 
cancer. Total gastrectomy was obtained and the patohistology report was signet ring cell carcinoma, 
stage T3N3M0. Computer tomography (CT) was done before the operative treatment and 6 months after 
the treatment. The CT before the treatment did not show any presents of peritoneal metastasis, there 
were no signs of peritoneal involvement. The next CT was done 6 months after the treatment where 
there was a sign of peritoneal involvement, with the diffuse spread of metastatic deposits (MS) all over 
the peritoneum. The present study showed a positive correlation between a more advanced T-stage and 
N-stage and the risk of presenting with PC. In literature, these factors were also associated with worse 
survival. This patient survival period was 4 months after diagnosis of peritoneal carcinomatosis with 
correlate with the data from the literature were median survival of patients with other metastases was 
14 months, but only 4 months for patients with PC.
Conclusion: Over 70% of gastric cancer patients undergoing surgery with curative intent will develop 
intra-abdominal recurrence in the course of the disease. The spread of malignant cells into the peritoneal 
cavity during surgery is one of the possible mechanisms for this phenomenon. PC is a frequent condition 
in patients presenting with gastric cancer, especially in younger patients with advanced tumor stages.
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developing countries [3]. Radical operation is the main treatment 
for gastric cancer, but the recurrence rate following surgery is high 
due to the early dissemination of cancer cells via the lymphatic 
system (about 40-80%) in advanced gastric cancer [4,5]. Western 
surgical studies have shown that most patients present with tumors 
that penetrated the submucosa, they have a 5-year survival rate of 
20-30% [6]. Postoperative chemotherapy is a standard treatment 
component of resectable gastric cancer and has improved patient 
outcomes (Figure 1). Treatment results of adjuvant chemotherapy 
may depend on the interaction between residual cancers and 
anticancer drugs [7-9]. Peritoneum and liver are the most 
common metastatic sites among patients with gastric cancer. 
Peritoneal carcinomatosis (PC) can lead to bowel obstruction and 
the formation of massive amounts of malignant ascites, therefore 
resulting in death. Although of its fatal consequences, the incidence 
of PC in gastric cancer is currently unknown [10,11].
PC is an important and not rare cause of morbidity and 
mortality among patients with gastric cancer [12]. The median 
survival period of patients with liver metastasis is 14 months but 
it is only 4 months for patients with PC (Figure 2). PC is a frequent 
condition in patients presenting with gastric cancer, especially in 
younger patients with advanced tumor stages [13,14]. Younger 
age (less than 60 years) female gender, advanced T- and N-stage, 
a primary tumor of signet ring cells or linitis plastica, and primary 
tumors covering multiple anatomical locations of the stomach 
were all associated with a higher odds ratio of developing PC. PC 
is a frequent condition in patients presenting with gastric cancer, 
especially in younger patients with advanced tumor stages [15,16].
Figures 2A & 2B: Peritoneal carcinomatosis from signet ring cell gastric carcinoma in a 63-year-old woman. Axial 
arterial phase CT images in the level of the kidneys, revealed multifocal nodules in the peritoneal cavity, peritoneal 
enhancement and thickening (black arrows), and ascites (white arrows).
Case Report
Figures 3A & 3B: A 63-year-old woman with peritoneal carcinomatosis from signet ring cell gastric carcinoma. 
Enhanced computed tomographic (CT) images in the level of pelvis show a large amount of ascites (white arrows), 
nodular soft tissue thickening of the peritoneum (black arrows).
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This is a case of 62 years old woman, who was previously 
diagnosed by gastroscopy with gastric cancer. Preoperatively 
computer tomography (CT) scan on the abdomen and lungs was 
done and no distant metastases were found. The patient was 
operatively treated and total gastrostomy as surgery procedure 
was obtained. Patohistology finding was signet ring cell carcinoma, 
stage T3N3M0. This patient went under the standard protocol of 
chemotherapy. Six mounts after the treatment follow-up CT scan 
was done, where diffuse dissemination of metastatic deposits (MS) 
all over the peritoneum was found and the diagnosis of peritoneal 
carcinomatosis was established also it was accompanied with free 
fluid in the abdomen and pelvis-ascites (Figure 3).
Discussion
It is proven that there is a positive correlation between a more 
advanced T-stage and N-stage and the risk of presenting with PC. In 
literature, these factors were also associated with worse survival 
[17]. This has been documented before in patients with colorectal 
cancer, which supports the hypothesis that PC is caused by serosal 
infiltration of the primary tumor and subsequent shedding of 
malignant cells into the peritoneal cavity [18]. Furthermore, patients 
with a primary signet ring cell or linitis plastica tumor had a higher 
risk of being diagnosed with synchronous PC as was recently also 
shown for the development of metachronous PC [19]. Identification 
of signet ring cell tumors may be important as this histological 
subtype has also been shown to have a negative prognostic impact 
on survival and has a poor response to chemotherapy [20,21]. The 
presence of PC had a profound negative impact on survival with 
a median survival of only 4 months [22]. In an attempt to treat 
advanced gastric cancer, different chemotherapeutic regimens have 
been investigated [23]. 
Cochrane review and meta-analysis demonstrated a convincing 
benefit for chemotherapy over best supportive care (three studies, 
n5184). In total, 35 trials with a total of 5,726 patients were 
included, which showed that combination chemotherapy, including 
5-FU, anthracyclines, and cisplatin gave the best results compared 
to conventional chemotherapy [24]. Recently, the implementation 
of a multimodality treatment including aggressive cytoreductive 
surgery combined with heated intraperitoneal chemotherapy 
(HIPEC) has led to promising results in selected patients with 
peritoneal malignancies of various origins, including colonic and 
ovarian cancer, mesothelioma and pseudomyxoma peritonei [25].
Conclusion
Over 70% of gastric cancer patients undergoing surgery 
with curative intent will develop intra-abdominal recurrence 
in the course of the disease. The spread of malignant cells into 
the peritoneal cavity during surgery is one of the possible 
mechanisms for this phenomenon. Given the bad prognosis of 
peritoneal dissemination, a strategy aimed at the prevention of PC 
by aggressive local treatment of patients at risk seems a realistic 
approach. PC is a frequent condition in patients presenting with 
gastric cancer, especially in younger patients with advanced tumor 
stages. Given the detrimental influence of PC on survival, efforts 
should be undertaken to further explore the promising results 
that were obtained in preventing or treating this condition with 
multimodality strategies.
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